Drug intelligence / Profile preview

cindigomab

Development stage: Preclinical
Lead developer: College of Medicine
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Cindigomab is an immuno-detection point inhibitor, specifically a PD-1 monoclonal antibody. It is being investigated in a clinical trial for the treatment of elderly acute myeloid leukemia, particularly in patients with increased leukemia residual disease or recurrence after microtransplantation, where it is used in combination with azacytidine.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on cindigomab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cindigomab.

Explore the full profile